Factors affecting interindividual differences in clozapine response: a review and case report
- 31 March 2011
- journal article
- case report
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 26 (3) , 177-187
Abstract
Objective: Clozapine is the most powerful new‐generation antipsychotic. Although this drug leads to great therapeutic benefits, two types of undesirable conditions frequently occur with its use: side effects and resistance to treatment. Therapeutic drug monitoring of clozapine would be very useful to avoid both these situations. The necessity of monitoring the therapy is the result of a wide interindividual variability in the metabolism of clozapine. In this review, we highlight all the conditions underlying this variability, analyzing them one by one.Methods: Relevant literature was identified through a search of MEDLINE and PubMed. In addition, the case of a treatment‐resistant patient with accelerated metabolism of clozapine is reported as representative of utility of therapeutic drug monitoring in terms of clozapine dose adjustment.Results: Genetic polymorphisms of cytochrome P450 enzymes and of neurotransmitter receptors; drug interactions; interactions of clozapine with other substances such as food and drink; smoking; and nonmodifiable variables such as age, ethnicity, and gender have been examined in relation to the existing scientific literature. The laboratory techniques that clinicians could use to identify these variables and adequate therapies are also reviewed. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 72 references indexed in Scilit:
- Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2The AAPS Journal, 2009
- Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian populationBritish Journal of Clinical Pharmacology, 2003
- Genetic Predictors of Therapeutic Response to ClozapineCNS Drugs, 2002
- Focus on ClozapineCurrent Medical Research and Opinion, 2001
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese PopulationJapanese Journal of Cancer Research, 1999
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlationsPharmacogenetics, 1996
- Association between clozapine response and allelic variation in the 5-HT2C receptor geneNeuroReport, 1995
- Factors affecting the polycyclic aromatic hydrocarbon content of cereals, fats and other food productsFood Additives & Contaminants, 1991